Search
-
GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)
Media
GSK & HSG announced, EC has granted marketing authorisation for Benlysta as therapy in patients with active autoantibody-positive SLE.
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-receive-european-authorisation-for-benlysta-belimumab/
First published: 14 July 2011
-
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
Media
ViiV today announced that the US FDA has approved Rukobia (fostemsavir), 600 mg extended-release tablets.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available/
First published: 02 July 2020
-
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
Media
The approval is based on the pivotal phase III ATLAS and FLAIR studies that included more than 1,100 patients from 16 countries.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-of-cabenuva-cabotegravir-rilpivirine-the-first-and-only-complete-long-acting-regimen-for-hiv-treatment/
First published: 21 January 2021
-
GSK publishes 2009 Corporate Responsibility Report
Media
In its 2009 Corporate Responsibility Report published online today, GSK reiterated its commitment to running its business responsibly.
https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2009-corporate-responsibility-report/
First published: 15 March 2010
-
GlaxoSmithKline and Human Genome Sciences announce topline 76-week results of phase 3 trial of Benlysta™ in systemic lupus erythematosus
Media
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) and today announced topline secondary endpoints from BLISS-76.
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-topline-76-week-results-of-phase-3-trial-of-benlysta-in-systemic-lupus-erythematosus/
First published: 19 April 2010
